Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.

Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

Bristol-Myers Squibb Company (NYSE:BMY ) Q4 2022 Earnings Conference Call February 2, 2023 9:00 AM ET Company Participants Timothy Power - VP & Head, IR Giovanni Caforio - Chairman & CEO David Elkins - EVP & CFO Christopher Boerner - EVP & Chief Commercialization Officer Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development Conference Call Participants Geoffrey Meacham - Bank of America Chris Shibutani - Goldman Sachs Christopher Schott - JPMorgan Seamus Fernandez - Guggenheim Securities Stephen Scala - Cowen and Company Timothy Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo Carter Gould - Barclays Matthew Phipps - William Blair Robyn Karnauskas - Truist Securities Olivia Brayer - Cantor Fitzgerald Andrew Baum - Citigroup Colin Bristow - UBS Operator Good morning. My name is Dennis, and I will be your conference operator today.

Bristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call Transcript

Bristol Myers (BMY) delivered earnings and revenue surprises of 6.43% and 2.37%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bristol Myers Squibb (BMY) Q4 Earnings and Revenues Surpass Estimates

Bristol Myers Squibb beat fourth-quarter expectations Thursday and offered a strong profit outlook, leading BMY stock to rise. The post Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook appeared first on Investor's Business Daily.

Bristol Myers Jumps On Fourth-Quarter Beat Strong Earnings Outlook

Bristol Myers posts fourth-quarter earnings of $1.82 a share on revenue of $11.4 billion.

Bristol Myers Stock Rises as Revenue Falls on Lower Revlimid Sales but Profit Tops Estimates

Shares of Bristol Myers Squibb Co. BMY, -1.95% gained 0.9% in premarket trading on Thursday after the company announced better-than-expected earnings for the fourth quarter of 2022. Bristol Myers Squibb had a profit of $2.0 billion, or 95 cents per share, in the fourth quarter, down from $2.3 billion, or $1.07 per share, in the same quarter in 2021.

Bristol Myers Squibb sees revenue fall in Q4

NEW YORK--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2022, which reflect robust growth of the in-line and new product portfolios, driven by strong commercial execution and continued progress of the company's pipeline.

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022

ConocoPhillips

Merck

Sirius XM Holdings Inc

In late morning trading Tuesday, the Dow Jones industrials were up 0.28%, the S&P 500 up 1.02% and the Nasdaq up 0.66%.

Earnings Previews: Bristol-Myers Squibb, ConocoPhillips, Merck, Sirius XM

Guardant Health Inc

Illumina

Pfizer

Learn about some of the leading cancer stocks in the U.S stock market this year.

Investing in Cancer Stocks

A decline in Revlimid sales will likely more than offset sales growth for Eliquis, Opdivo, and Reblozyl.

How Will Bristol Myers Squibb Stock Trend Post Q4 Results?

Microsoft

These companies are established leaders in their respective fields.

2 Top Dividend Stocks to Buy in 2023 and Hold Forever

ABM Industries

Archer-Daniels-Midland Company

Applied Industrial Technologies

Arthur J. Gallagher & Co.

Alamo Group

Ally Financial

American Tower

Air Products and Chemicals

Ames National

Aptargroup

American Water Works

Bank of New York Mellon

Blackrock Inc

Bank of Marin Bancorp

Brady Corporation

Brown & Brown

Camden National

Cadence Bank

Casey's General Stores

Cambridge Bancorp

City Hld

Comcast

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of January 29

Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?

PRINCETON N.J.--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Reblozyl ® (luspatercept) as a treatment for adult patients with anemia associated with non‑transfusion-dependent (NTD) beta thalassemia. The recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the European Union (EU). Upon approval, this would represent the third authorized indication for Reblozyl in the EU.

Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia

PRINCETON, N.J.--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).

Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bristol Myers Squibb (BMY) Q4 Earnings Expected to Decline

PRINCETON, N.J.--( BUSINESS WIRE )--Bristol Myers Squibb (NYSE: BMY) today announced topline results from TRANSCEND CLL 004, a Phase 1/2, open-label, single-arm, multicenter study evaluating Breyanzi (lisocabtagene maraleucel) in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Results from TRANSCEND CLL 004 showed the study met the primary endpoint of complete response rate compared to historical control in the prespecified subset of patients with R/R CLL that was refractory to a BTK inhibitor and pretreated with a BCL-2 inhibitor. No new safety signals were reported for Breyanzi in this study.

Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

PayPal

TC Energy

These stocks are good value buys for the long haul.

3 Buffett-Type Stocks to Buy Right Now

Align Technology

Alnylam Pharmaceuticals

Baxter

BeiGene

Royalty Pharma

Teleflex

Universal Health Services

Veeva Systems

Walgreens

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.

5 Best and Worst Performing Health Care Stocks in December 2022

PRINCETON, N.J.--( BUSINESS WIRE )--The Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) established by the Bristol Myers Squibb Foundation (BMSF) today announced that Amgen, a global biotechnology company, has committed to contribute $8 million over the next four years. This contribution will enable the program to reach additional physicians and medical students, further expanding the initiative that aims to extend the reach of clinical trials in underserved patient populations in U.S. communities.

The Robert A. Winn Diversity in Clinical Trials Award Program Established by the Bristol Myers Squibb Foundation to Expand with Amgen's Commitment of $8 Million

While foreign competitors Novartis and Roche scored better than Bristol Myers in my recent pipeline analysis, BMY is the best US option. This article will revisit the metrics that allowed BMY to beat competitors such as Pfizer and Merck.

Why Bristol Myers Squibb Is The Better Buy From U.S. Large Cap Pharma

Apple

AbbVie

Abbott Labs

Aflac

Ameriprise Financial

Amazon

Bank of America

Becton, Dickinson and Co.

Citigroup

Cardinal Health

Caterpillar

Cisco Systems

In 2015, I started publishing updates regarding my dividend growth portfolio, and I keep doing so every quarter. This is part of being transparent with my readers, so they can see what I hold and its correlation with my writing.

My Dividend Growth Portfolio - Q4 2022 Summary

News for Bristol-Myers Stock (BMY)